


**Amended Claims**

1) (currently amended) An antiparasitic formulation, wherein:  
the formulation characterized in that it comprises one or more spinosyns, as  
active ingredients, spinosyn(s) in combination with one or more compounds of a  
compound of formula (I) and/or salts thereof;

formula (I) corresponds in structure to:



and salts thereof, in which

Ar is 2,6-dichloro-4-trifluoromethylphenyl or 2-nitro-4-trifluoromethylphenyl;

A is S(O)<sub>m</sub>, ~~-CH=CH-~~ CH=CH, O<sub>2</sub> or NH;

as to W and Z:

W is N<sub>1</sub> and Z is CR<sup>5</sup>; or

W is CR<sup>1</sup><sub>1</sub> and Z is N or CR<sup>5</sup>;

R<sup>1</sup> is hydrogen, optionally substituted alkyl, halogen<sub>1</sub> or R<sup>20</sup>S(O)<sub>q</sub>;

R<sup>2</sup> and R<sup>3</sup> are independently hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted [[or]] alkynyl, ~~each of which is optionally substituted~~, aryl, cyano, halogen, nitro, YR<sup>20</sup>, S(O)<sub>2</sub>NR<sup>8</sup>R<sup>9</sup>, CHO, NR<sup>8</sup>R<sup>9</sup>, or CYNR<sup>8</sup>R<sup>9</sup>;

R<sup>4</sup> is hydrogen, optionally substituted alkyl, optionally substituted alkenyl, acyl<sub>1</sub> or optionally substituted alkoxy carbonyl;

R<sup>5</sup> is hydrogen, alkyl, optionally substituted amino<sub>1</sub> or halogen;

R<sup>8</sup> and R<sup>9</sup> are independently the same or different and are hydrogen, optionally substituted alkyl, acyl<sub>1</sub> or aryl;

R<sup>20</sup> is optionally substituted alkyl;

Y is O or S;

Express Mail: EV 630723785 US  
Preliminary Amendment A  
Appl. No. TBA  
April 26, 2006

m is ~~[[0]]~~ zero, 1, or 2;

p is ~~[[0]]~~ zero or 1;

n is ~~[[0]]~~ zero, 1, or 2; ~~[[and]]~~

q is ~~[[0]]~~ zero, 1, or 2; ~~and in which a)~~

any alkyl, alkoxy, or ~~[[and]]~~ alkylthio comprises groups is of 1 to 4 carbon atoms;

~~[[b)]]~~

any alkenyl or alkynyl comprises groups is of 2 to 5 carbon atoms; ~~[[c)]]~~

the alkyl, alkoxy, alkylthio, alkenyl, or alkynyl portion of any substituted alkyl, alkoxy, alkylthio, alkenyl, or alkynyl ~~[[group]]~~ is substituted by one or more substituents independently of the same or different groups selected from the group consisting of halogen,  $\text{YR}^{20}$ , dihalocyclopropyl, cyano, nitro, optionally substituted amino, acyloxy, and aryl; ~~[[d)]]~~

any aryl ~~[[group]]~~ is phenyl ~~[[,]]~~ optionally substituted ~~[[,]]~~ by halogen, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio, haloalkylsulphonyl, cyano, or nitro; ~~[[e)]]~~

any acyl ~~[[group]]~~ is alkanoyl comprising ~~[[of ]]~~ 1 to 4 carbon atoms, ~~[[or]]~~ alkylsulphonyl, or haloalkylsulphonyl; ~~[[and f)]]~~

any optionally substituted amino groups is of formula  $\text{NR}^8\text{R}^9$ ; and ~~with the proviso that~~

$\text{R}^4$  is not alkyl when:

W is  $\text{CR}^1$ , ~~[[and]]~~

Z is  $\text{CR}^5$ , and

n and p are both zero 0,  ~~$\text{R}^4$  is not alkyl.~~

2) (currently amended) The formulation according to claim 1, wherein ~~characterized in that~~ the compound of formula (I) is 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole or a salt thereof (compound 22e).

Express Mail: EV 630723785 US  
Preliminary Amendment A  
Appl. No. TBA  
April 26, 2006

3) (currently amended) The formulation according to claim 1, wherein the formulation comprises ~~or 2 characterized in that the spinosyns are~~ a mixture of [[any]] two or more spinosyns ~~spinosyn compounds~~.

4) (currently amended) The formulation according to claim 3, wherein ~~characterized in that~~ the mixture is spinosad.

5) (currently amended) The formulation according to ~~any of claims~~ claim 1, wherein the ratio of ~~4 characterized in that~~ the one or more compounds ~~compound~~ of formula (I) (and/or salts thereof) to the [[and]] one or more spinosyns is from ~~are present in a ratio of~~ 1:10 to 10:1.

6) (currently amended) A method of controlling an ectoparasite infestation, wherein the method comprises simultaneously or sequentially administering: Use of one or more spinosyns, and ~~at least~~ one or more compounds of ~~compound according to~~ formula (I) recited in claim 1 (and/or salts thereof) as active ingredients in the manufacture of a medicament for controlling an ectoparasite infestation by administering the active ingredients in combination, either simultaneously or sequentially.

7) (currently amended) The method [[Use]] according to claim 6, wherein the method comprises administering: active ingredients are spinosad, and 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole or a salt thereof ~~and spinosad~~.

8) (currently amended) The method [[Use]] according to claim 6, [[or 7,]] wherein the one or more spinosyns and one or more compounds of ~~at least one compound~~

· Express Mail: EV 630723785 US  
Preliminary Amendment A  
Appl. No. TBA  
April 26, 2006

~~according to formula (I) (and/or salts thereof) are administered medicament is for controlling an ectoparasite infestation by administering the active ingredients simultaneously.~~

9) (currently amended) The method [[Use]] according to claim 8, wherein the one or more spinosyns and one or more compounds of formula (I) (and/or salts thereof) are medicament comprises the active ingredients in a single preparation.

10) (currently amended) The method [[Use]] according to claim 6, wherein the ectoparasites are ticks.

11) (currently amended) The method [[Use]] according to claim 6, wherein the ectoparasites are fleas.

**Please add the following new claims:**

12) (new) The formulation according to claim 2, wherein the ratio of the 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) to the one or more spinosyns is from 1:10 to 10:1.

13) (new) The formulation according to claim 2, wherein the formulation comprises a mixture of two or more spinosyns.

14) (new) The formulation according to claim 3, wherein the ratio of the one or more compounds of formula (I) (and/or salts thereof) to the two or more spinosyns is from 1:10 to 10:1.

15) (new) The formulation according to claim 4, wherein the ratio of the one or more compounds of formula (I) (and/or salts thereof) to the spinosad is from 1:10 to 10:1.

16) **(new)** The formulation according to claim 13, wherein the ratio of the 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) to the two or more spinosyns is from 1:10 to 10:1.

17) **(new)** The formulation according to claim 13, wherein the mixture is spinosad.

18) **(new)** The formulation according to claim 17, wherein the ratio of the 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) to the spinosad is from 1:10 to 10:1.

19) **(new)** The method according to claim 7, wherein the spinosad and 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) are administered simultaneously.

20) **(new)** The method according to claim 19, wherein spinosad and 5-chloro-1-(2,6-dichloro-4-trifluoromethylphenyl)-4-(4,5-dicyano-1H-imidazol-2-yl-3-methyl-1-H pyrazole (or salt thereof) are in a single preparation.

21) **(new)** A use of one or more spinosyns in combination with one or more compounds of formula (I) (and/or salts thereof) recited in claim 1, wherein the use comprising making a medicament for controlling an ectoparasite infestation by simultaneously or sequentially administering the one or more spinosyns in combination with one or more compounds of formula (I) (and/or salts thereof).